Tartaric Acid

If you regularly drink wine or eat grapes and want to know what your body is actually absorbing, this test answers that question with a number rather than a guess. Food frequency questionnaires are famously unreliable, and self-reported alcohol intake is often off by a wide margin. A urine measurement sidesteps both problems.

This is a research-grade marker rather than a diagnostic test. It does not screen for disease. What it does well is verify whether the wine and grape habits you think you have are matched by what shows up inside your body, which becomes useful when you are trying to connect those habits to cardiovascular markers, inflammation, or other lab changes.

What This Marker Actually Reflects

Tartaric acid is one of the main acids in grapes. Your body does not make it in any meaningful amount. When you eat grapes or drink wine, your gut absorbs some of the tartaric acid intact, your kidneys filter it, and a portion of what you ingested ends up in your urine over the following day. Because nothing else in a typical diet contributes meaningfully to this molecule, the level in your urine tracks back to grape-derived intake with unusual specificity.

A controlled feeding trial that fed people graded grape doses found a strong linear relationship between grape intake and 24-hour urinary tartaric acid (r² = 0.90). That level of dose-response is rare for any dietary biomarker. In that study, spot urine samples did not perform nearly as well, which is why collection method matters so much for this test.

How It Reads Wine Intake

In a PREDIMED sub-study, urinary tartaric acid tracked self-reported wine consumption closely enough to separate wine consumers from non-consumers with reasonably strong discrimination (AUC 0.818, 95% CI 0.76 to 0.87). AUC is a measure of how well a test distinguishes two groups, where 1.0 is perfect and 0.5 is a coin flip. In the main PREDIMED cardiovascular outcomes analysis, urinary tartaric acid correlated with self-reported wine consumption at r = 0.46.

The practical implication: if you want to verify whether you are actually in a moderate wine drinking pattern (as opposed to overestimating or underestimating what you pour), this number tells you. It also tells your clinician something more reliable than your own report when interpreting cardiovascular labs.

Cardiovascular Associations in High-Risk Adults

In a PREDIMED sub-study of postmenopausal women at high cardiovascular risk, higher urinary tartaric acid (reflecting more wine intake) was associated with lower total and LDL cholesterol after extensive adjustment. This was not a randomized intervention, so it cannot prove that wine itself caused the lipid difference, but the association survived controlling for the usual confounders.

A separate analysis of high-risk adults found that higher urinary tartaric acid was linked to lower levels of two adhesion molecules called sICAM-1 and sVCAM-1, which are signals that the cells lining your blood vessels are in an inflamed, sticky state that helps plaque form. Lower levels of these markers point to a calmer vascular wall.

The main PREDIMED cardiovascular outcomes paper, published in the European Heart Journal in 2025, went further: in high-risk Mediterranean adults, light-to-moderate wine consumption measured by urinary tartaric acid was prospectively associated with lower cardiovascular event rates, with a hazard ratio of 0.50 for the 12 to 35 microgram per milliliter range (P = 0.035). An accompanying editorial in the same journal framed these results within the longer history of the French paradox and the value of objective intake biomarkers.

These findings come from observational cohorts in older, high-risk Mediterranean populations. They do not extend automatically to younger people, lighter drinkers, or non-Mediterranean diets, and they do not prove that wine causes the benefit. What they do say is that for someone tracking wine intake in this kind of context, the biomarker is closely linked to recognized cardiovascular signals.

Reconciling the Wine Question

It would be easy to read those cardiovascular findings as proof that more wine is better. That is not what the evidence shows. The biomarker reflects intake, not health. People who drink moderately in a Mediterranean dietary pattern look different on average from people who do not, and some of that difference shows up in lipids and inflammation markers. The biomarker is a way to confirm intake. It is not a vote in favor of drinking more.

Appearances in Disease Metabolomics

A systematic review of urinary metabolomics in colorectal cancer found tartaric acid among several urinary metabolites that were lower in cancer cases compared with controls. It showed up as one component of multi-metabolite signatures rather than as a standalone diagnostic. The review reported strong AUC values for combinations of multiple compounds, but no individual sensitivity or specificity for tartaric acid alone.

In a study of autistic children, urinary tartaric acid was higher in those with co-occurring atopic dermatitis on initial analysis, but the difference did not survive multivariable adjustment. The signal here is too thin to act on. These exploratory findings are why the marker has not become a diagnostic test for any disease.

Why a 24-Hour Collection Is Preferred

The grape feeding trial was explicit: a full 24-hour collection produced the strongest dose-response relationship, while spot samples performed less well. The marker rises and falls across the day depending on when you last had wine or grapes, so a single random sample can give you a number that has more to do with what you drank in the past few hours than with your typical pattern. A separate randomized crossover trial showed that a creatinine-normalized morning spot urine can still correlate strongly with a fixed wine dose (r = 0.922) in a controlled setting, but in free-living conditions a 24-hour collection remains the standard for quantitative assessment.

If your test uses a spot sample with creatinine normalization, treat the result as a directional snapshot rather than a precise measurement of habitual intake. For meaningful tracking, a full 24-hour collection is the standard.

Tracking Your Trend

A single reading is mostly a confirmation that wine and grapes reached your bloodstream in the day before the test. Where the marker becomes interesting is when you track it alongside changes in your habits or alongside other labs. If you are testing whether moderate wine consumption shifts your lipid panel or inflammation markers, repeating tartaric acid at the same intervals confirms whether your intake is actually steady or whether you have drifted higher or lower.

No study has validated a specific retesting cadence for this biomarker, so any schedule is practical rather than evidence-based. One reasonable approach for someone using this as a dietary verification tool is a baseline 24-hour collection, a repeat at three to six months if you have changed your wine or grape intake, and an annual check if you are tracking long-term lifestyle patterns. Because cutpoints are not standardized, your own readings over time are more useful than any single reference range.

When Results Can Be Misleading

• Spot vs 24-hour collection: a random urine can swing dramatically depending on when you last had wine, grapes, grape juice, or even some grape-derived food additives. A full 24-hour collection more reliably reflects habitual intake.
• Recent grape exposure: tartaric acid appears in grape juice, raisins, wine vinegar, and some processed foods and supplements. Intake in the day before your test can produce a high reading that has nothing to do with your usual diet.
• No standardized cutpoints: there is no universally accepted normal range. Different labs may use different methods, so comparing your number to a friend's or to an internet reference can mislead.
• Limited evidence outside Mediterranean cohorts: most clinical research comes from older, high-risk Spanish adults. Direct transfer of any threshold or association to younger people or different diets is not well established.

Decision Pathway for Unexpected Results

No published clinical decision pathway exists for this biomarker, so the steps below are practical rather than guideline-based. An unexpectedly high level in someone who reports rarely drinking wine usually means hidden grape-derived intake (juices, sauces, vinegars, dried fruit) rather than disease. Before chasing it as a clinical finding, review your food and drink in the 24 to 48 hours before collection. If the result still does not match your habits, consider a repeat 24-hour collection on a controlled diet.

An unexpectedly low level in someone who reports daily wine intake is worth taking seriously: it may mean you are drinking less than you think, your collection was incomplete, or the sample was a spot rather than a true 24-hour pool. If you are using this marker alongside a lipid panel or inflammation markers to understand how wine fits into your cardiovascular picture, share both results with a physician familiar with preventive cardiology. The number gains meaning when interpreted alongside ApoB, hs-CRP, and your full lipid profile, not on its own.